{"id":"https://openalex.org/W4362533869","doi":"https://doi.org/10.1158/1535-7163.22499200","title":"Supplementary Figure 6 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib","display_name":"Supplementary Figure 6 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib","publication_year":2023,"publication_date":"2023-04-03","ids":{"openalex":"https://openalex.org/W4362533869","doi":"https://doi.org/10.1158/1535-7163.22499200"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.22499200","doi":"https://doi.org/10.1158/1535-7163.22499200","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.22499200","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"supplementary-materials","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/1535-7163.22499200","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5054528392","display_name":"Ondrej Kalous","orcid":"https://orcid.org/0000-0002-3821-6603","observed_orcids":["https://orcid.org/0000-0002-3821-6603"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ondrej Kalous","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045387212","display_name":"Dylan F. Conklin","orcid":"https://orcid.org/0000-0003-4708-0071","observed_orcids":["https://orcid.org/0000-0003-4708-0071"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Dylan Conklin","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009971985","display_name":"Amrita J. Desai","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Amrita J. Desai","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028010756","display_name":"Neil A. O\u2019Brien","orcid":"https://orcid.org/0000-0001-7408-1091","observed_orcids":["https://orcid.org/0000-0001-7408-1091"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Neil A. O'Brien","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5104110850","display_name":"Charles Ginther","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Charles Ginther","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Lee Anderson","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lee Anderson","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5114257754","display_name":"David J. Cohen","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"David J. Cohen","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052493398","display_name":"Carolyn D. Britten","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Carolyn D. Britten","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Ian Taylor","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ian Taylor","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074923974","display_name":"James G. Christensen","orcid":"https://orcid.org/0000-0003-1835-0335","observed_orcids":["https://orcid.org/0000-0003-1835-0335"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"James G. Christensen","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015491002","display_name":"Dennis J. Slamon","orcid":"https://orcid.org/0000-0002-6330-498X","observed_orcids":["https://orcid.org/0000-0002-6330-498X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Dennis J. Slamon","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5073989429","display_name":"Richard S. Finn","orcid":"https://orcid.org/0000-0003-2494-2126","observed_orcids":["https://orcid.org/0000-0003-2494-2126"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Richard S. Finn","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10696","display_name":"Gastric Cancer Management and Outcomes","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/dacomitinib","display_name":"dacomitinib","score":1.0},{"id":"https://openalex.org/keywords/her2-amplified-breast-cancer","display_name":"HER2-amplified breast cancer","score":0.902999997138977},{"id":"https://openalex.org/keywords/trastuzumab-resistance","display_name":"trastuzumab resistance","score":0.9419999718666077},{"id":"https://openalex.org/keywords/lapatinib-resistance","display_name":"lapatinib resistance","score":1.0},{"id":"https://openalex.org/keywords/apoptosis","display_name":"apoptosis","score":0.8970000147819519},{"id":"https://openalex.org/keywords/bt474-cells","display_name":"BT474 cells","score":0.9440000057220459},{"id":"https://openalex.org/keywords/skbr3","display_name":"SKBR3","score":0.9950000047683716},{"id":"https://openalex.org/keywords/her2-inhibitors","display_name":"HER2 inhibitors","score":0.4909999966621399},{"id":"https://openalex.org/keywords/cell-proliferation","display_name":"cell proliferation","score":0.48100000619888306}],"concepts":[{"id":"https://openalex.org/C2777329042","wikidata":"https://www.wikidata.org/wiki/Q420323","display_name":"Lapatinib","level":5,"score":0.9840308427810669},{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.937562108039856},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5375605821609497},{"id":"https://openalex.org/C190283241","wikidata":"https://www.wikidata.org/wiki/Q14599311","display_name":"Apoptosis","level":2,"score":0.4835774302482605},{"id":"https://openalex.org/C2779707156","wikidata":"https://www.wikidata.org/wiki/Q5611758","display_name":"Growth inhibition","level":3,"score":0.4246927499771118},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.41492941975593567},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.4120196998119354},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.33754295110702515},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.33074092864990234},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3277336359024048},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.28350546956062317},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.06538721919059753}],"mesh":[],"locations_count":3,"locations":[{"id":"doi:10.1158/1535-7163.22499200","doi":"https://doi.org/10.1158/1535-7163.22499200","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.22499200","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"doi:10.1158/1535-7163.22499200.v1","doi":"https://doi.org/10.1158/1535-7163.22499200.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1535-7163.22499200.v1","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_6_from_Dacomitinib_PF-00299804_an_Irreversible_Pan-HER_Inhibitor_Inhibits_Proliferation_of_HER2-Amplified_Breast_Cancer_Cell_Lines_Resistant_to_Trastuzumab_and_Lapatinib/22499200/1/files/39957580.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"pmh:oai:figshare.com:article/22499200","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/journal_contribution/Supplementary_Figure_6_from_Dacomitinib_PF-00299804_an_Irreversible_Pan-HER_Inhibitor_Inhibits_Proliferation_of_HER2-Amplified_Breast_Cancer_Cell_Lines_Resistant_to_Trastuzumab_and_Lapatinib/22499200","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1158/1535-7163.22499200","doi":"https://doi.org/10.1158/1535-7163.22499200","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.22499200","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9391000270843506,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4362533869.pdf","grobid_xml":"https://content.openalex.org/works/W4362533869.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2153343658","https://openalex.org/W4362492627","https://openalex.org/W2801370440","https://openalex.org/W2563504190","https://openalex.org/W1597931794","https://openalex.org/W2077609445","https://openalex.org/W2498025682","https://openalex.org/W2479078614","https://openalex.org/W2323584401","https://openalex.org/W2585923853"],"abstract_inverted_index":{"PDF":[0],"file,":[1],"60K,":[2],"Effect":[3],"of":[4],"dacomitinib":[5],"on":[6],"apoptosis":[7],"in":[8],"BT-474":[9],"and":[10,14,19],"SK-BR-3":[11],"parental":[12],"lines":[13,15],"resistant":[16],"to":[17],"trastuzumab":[18],"lapatinib.":[20]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2023-04-06T00:00:00"}